ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0708

Severe AKI in SARS-COVID-19 Patients from a Tertiary Hospital in Rhode Island

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Kota, Harshitha, Brown University, Providence, Rhode Island, United States
  • Mitchell, Kevin, Brown University, Providence, Rhode Island, United States
  • Tang, Jie, Brown University, Providence, Rhode Island, United States
Background

The clinical features & outcomes of COVID-19 patients who developed severe AKI are still being elucidated.

Methods

42 patients with COVID-19 infection who developed KDOGI stage 3 AKI were identified from March 1 to May 15, 2020, at Rhode Island Hospital, a large tertiary teaching hospital. Their clinical presentations and outcomes are presented. The data in table 1 were presented as mean (± SD), median (IQR), or # (%).

Results

The baseline characteristics are outlined in table 1. Among them, 88% were admitted to ICU, 83% were intubated and needed pressor support. 71% received renal replacement therapy (RRT)(56% on CVVHDF). The mean duration of RRT and ICU stay were 6 and 14 days, respectively. 33 participants received treatment for COVID-19, among them 14 (33%) received Remdesivir(RDV), 6 (14%) received convalescent plasma(CP), 4 (10%) received hydroxychloroquine(HCQ), and 25 (60%) also received azithromycin. The mortality rates were 15% in the RDV group, 67% in the CP group, and 75% in the HCQ group. The mortality was 67% in those without any treatment. At the 60-day follow-up, 11 (26%) were discharged alive, 21 (50%) died. Those who died were older (mean age 71 vs. 61), having higher Charlson Comorbidity Index (4.7 vs 3.0), more likely to have diabetes (71% vs. 61%) and coronary artery disease (38% vs. 24%).

Conclusion

The mortality rate of SARS-COVID patients who developed severe AKI is high in our cohort. Future larger scale studies are needed to elucidate the causes of this high mortality.

Table 1 Baseline and Presenting characteristics of the cohort
 Total Participants, n=42
Age64(56-72)
Sex, Male33(79%)
Hispanic19(45%)
White12(29%)
HTN35(83%)
DM28(67%)
HLD26(62%)
CAD13(31%)
CHF6(14%)
COPD/Asthma4(10%)
Atrial fibrillation3(7%)
Baseline CKD20(48%)
Charlson Comorbidity Index3.7(±1.9)
Smoking,Never18(43%)
BMI31.4(±6.7)
Symptom, duration <1 week30(71%)

Funding

  • Clinical Revenue Support